Since its inception in 1984, the TIMI Study Group has been an Academic Research Organization dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease. We have led a wide array of trials, from phase I to phase IV, enrolling from less than 30 to more than 26,000 subjects, and with both industry and NIH support. Trials have been conducted in over 50 countries and at more than 5000 separate sites.
We investigate a broad array of therapeutic interventions in individuals across the spectrum of cardiovascular disease, ranging from prevention in those with risk factors, to emergent interventions in those with acute manifestations of disease. In addition, we have used our large database of clinical findings, biomarkers, and genotypes to enhance the understanding of cardiovascular disease and its risk factors.
By leading large-scale, international, randomized controlled trials of novel therapeutics and performing sophisticated analyses, we have been privileged to help shape the very practice of cardiovascular medicine for over a quarter of a century.
Current and Recent Trials
Recent News and Publications
11/12/2016 - AHA 2016 Scientific Sessions - TIMI Presentation Schedule
10/24/2016 - New Publication: Bonaca et al., Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial. 2016 JACC Cardiovasc Interv.
9/27/2016 - New Publication: Silverman et al., Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. 2016 JAMA.
9/20/2016 - New Publication: Bonaca et al., Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54. 2016 Circ.
9/15/2016 - TIMI Risk Score for Secondary Prevention Calculator -- now available